ByteBrief
We're a portrait publication through and through. Turn your phone back and your briefing picks up right where you left it.
(We tried widescreen once. It wasn't us.)

Toronto biotech Biossil raised $153 million USD at a $1 billion valuation, led by the OpenAI Startup Fund, with Founders Fund and others participating. The company buys failed drug candidates and revives them using AI. It exited stealth in April with $70 million and will use the new funds to expand clinical development and acquire more drug assets.
Tap to vote and see what everyone thinks.
Summary by ByteBrief